The pharmaceutical industry invests enormous amounts of resources (>€1 billion and >10 years) in the development of new products. External factors such as intensifying foreign competition and greater regulatory demands can negatively affect the profit margin, whereas the R&D productivity diminishes. To stay competitive and to maintain high R&D capabilities for developing new medicinal products, companies must make smart investment decisions to maximize their return on investment. Consequently, the entire lifecycle of a medicinal product must be effectively managed to ensure a sustained development through commercialization. This review critically assesses the current situation and the associated management strategies throughout the lifecycle of a medicinal product.

制药行业在开发新产品方面投入了大量资源（> 10亿欧元和> 10年）。外部竞争加剧和监管要求提高等外部因素可能对利润率产生负面影响，而研发生产率却下降。为了保持竞争力并保持开发新药产品的高研发能力，公司必须做出明智的投资决策，以最大程度地提高投资回报率。因此，必须有效管理药品的整个生命周期，以确保通过商业化实现持续发展。这项审查严格评估了整个医药产品生命周期中的当前状况和相关的管理策略。